SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.308
AS - Asia 2.072
EU - Europa 698
SA - Sud America 422
Continente sconosciuto - Info sul continente non disponibili 195
AF - Africa 83
OC - Oceania 6
Totale 5.784
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.173
SG - Singapore 677
BD - Bangladesh 386
IT - Italia 378
CN - Cina 320
BR - Brasile 289
VN - Vietnam 204
HK - Hong Kong 189
DE - Germania 73
IN - India 61
CA - Canada 48
MX - Messico 48
AR - Argentina 46
FR - Francia 42
ZA - Sudafrica 38
ID - Indonesia 34
JP - Giappone 34
RU - Federazione Russa 32
FI - Finlandia 30
GB - Regno Unito 30
UA - Ucraina 29
IQ - Iraq 25
EC - Ecuador 24
CO - Colombia 23
TR - Turchia 22
NL - Olanda 20
MY - Malesia 19
ES - Italia 15
MA - Marocco 13
PH - Filippine 13
VE - Venezuela 13
PK - Pakistan 12
JM - Giamaica 11
SA - Arabia Saudita 11
AE - Emirati Arabi Uniti 10
AT - Austria 8
CL - Cile 8
TN - Tunisia 8
NP - Nepal 7
UZ - Uzbekistan 7
AU - Australia 6
BO - Bolivia 6
DZ - Algeria 6
GT - Guatemala 5
IE - Irlanda 5
KG - Kirghizistan 5
PS - Palestinian Territory 5
UY - Uruguay 5
AL - Albania 4
CH - Svizzera 4
JO - Giordania 4
OM - Oman 4
PL - Polonia 4
PY - Paraguay 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
BB - Barbados 3
BG - Bulgaria 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
EG - Egitto 3
ET - Etiopia 3
IL - Israele 3
LB - Libano 3
LT - Lituania 3
PA - Panama 3
PE - Perù 3
SE - Svezia 3
SN - Senegal 3
AO - Angola 2
AZ - Azerbaigian 2
BH - Bahrain 2
CZ - Repubblica Ceca 2
EE - Estonia 2
GE - Georgia 2
GR - Grecia 2
KE - Kenya 2
KH - Cambogia 2
LV - Lettonia 2
NI - Nicaragua 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
AI - Anguilla 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
HN - Honduras 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
MQ - Martinica 1
MT - Malta 1
MU - Mauritius 1
NO - Norvegia 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
Totale 5.589
Salva come PNG Salva come JPEG
Città #
Santa Clara 452
Singapore 380
San Jose 315
Ashburn 212
Hong Kong 187
Council Bluffs 183
New York 105
Beijing 77
Ho Chi Minh City 73
Los Angeles 52
Hanoi 43
Milan 41
Mexico City 38
Bologna 37
Chicago 34
Tokyo 34
Dallas 30
Rome 28
Buffalo 26
Lauterbourg 23
Lappeenranta 21
São Paulo 21
Jakarta 19
Fairfield 17
Hefei 17
Orem 17
Palermo 16
Brooklyn 13
Cambridge 13
London 13
Ferrara 12
Kuala Lumpur 12
Naples 12
Chennai 11
Da Nang 11
Dhaka 11
Montreal 11
Munich 11
Phoenix 11
Salt Lake City 11
Toronto 11
Baghdad 10
Las Vegas 10
San Francisco 10
Seattle 10
Guayaquil 9
Houston 9
Newark 9
Rio de Janeiro 8
Atlanta 7
Bari 7
Curitiba 7
Elk Grove Village 7
Medellín 7
Paris 7
Amsterdam 6
Charlotte 6
City of London 6
Falkenstein 6
Fortaleza 6
Frankfurt am Main 6
Helsinki 6
Johannesburg 6
Kingston 6
Salvador 6
Sydney 6
Tashkent 6
Thái Bình 6
Woodbridge 6
Ankara 5
Boardman 5
Brasília 5
Caracas 5
Denver 5
Detroit 5
Dublin 5
Forest City 5
Guatemala City 5
Lahore 5
Moscow 5
Quito 5
Wilmington 5
Assago 4
Bangkok 4
Bhopal 4
Bishkek 4
Bogotá 4
Brescia 4
Bình Dương 4
Cleveland 4
Columbus 4
Delhi 4
Figino 4
Florence 4
Haiphong 4
La Paz 4
Manila 4
Miami 4
Montevideo 4
Muscat 4
Totale 2.999
Salva come PNG Salva come JPEG
Nome #
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 153
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 128
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients 109
P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients 106
How much of familial breast cancer risk is currently explained by the known genes? 103
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 98
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients 97
Relationship between imaging‐derived parameters and circulating microRNAs to study the degree of lung involvement in hospitalized geriatric patients with COVID‐19 pneumonia 93
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 91
Magnetic Resonance Imaging and 99Tc WBC-SPECT/CT Scanning in Differential Diagnosis between Osteomyelitis and Charcot Neuroarthropathy: A Case Series 85
The likelihood of being helped or harmed obtained from clinical trial results for cancer therapy: Can it really help? 84
To ablate or not to ablate? Outcomes of local ablative treatments (LAT) for oncogene addicted (OA) oligo-metastatic (OM) non-small cell lung cancer (NSCLC): A systematic review 84
The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative Diseases 80
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future 80
The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review 79
Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs 79
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients 78
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 78
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 78
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 76
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 75
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis 74
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis 71
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 71
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 70
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer 69
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer 68
DNA Methylation-derived biological age and long-term mortality risk in subjects with type 2 diabetes 67
Replicative Senescence-Associated LINE1 Methylation and LINE1-Alu Expression Levels in Human Endothelial Cells 66
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 66
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 66
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 65
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 65
Analysis of Germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 65
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 65
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy 65
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy? 64
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 63
Bortezomib: A new pro-apoptotic agent in cancer treatment 63
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 62
A headlight on liquid biopsies: a challenging tool for breast cancer management 60
The application of cancer stem cell model in malignant mesothelioma 59
The Association Between Hepatocellular Carcinoma and Gastrointestinal Adenocarcinoma: Is This a New Syndrome in Patients With Cirrhosis? A Case Series 57
Anti-endothelin drugs in solid tumors 57
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 57
BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 57
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 56
Cancer and the microbiome: Potential applications as new tumor biomarker 51
HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions 51
Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival 50
Editorial: Cancer biomarkers: molecular insights into diagnosis, prognosis, and risk prediction 42
P3.14.06 Attitude of Italian Physicians Towards Germline and Somatic Genetic Testing in Pleural Mesothelioma: Preliminary Results of a Nationwide Survey 42
Targeting RET-rearranged non-small-cell lung cancer: Future prospects 42
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 41
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 40
The Effects of Variant Allele Frequency for EGFR Mutation on Early Tumor Shrinkage and Deepness of Response to Osimertinib in Patients with Metastatic Non-Small Cell Lung Cancer: An Exploratory Analysis 40
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 40
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis 40
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 39
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 38
HER2-positive male breast cancer: An update 37
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 35
The role of 2D-Shearwave elastography in non invasive portal hypertension diagnosis 35
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: There is a sense in antisense? 35
Targeted therapies in hepatocellular carcinoma 34
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 34
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 33
Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma 33
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? 33
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 33
Molecular target therapy for bone metastasis: Starting a new era with denosumab, a RANKL inhibitor 32
Monoclonal antibodies in gastrointestinal cancers 32
Hypoxia and human genome stability: Downregulation of BRCA2 expression in breast cancer cell lines 32
Studio pilota sul valore predittivo dei livelli plasmatici di 9 fattori angiogenetici nella selezione di pazienti candidati alla biopsia prostatica 32
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 31
Ramucirumab and its use in gastric cancer treatment 31
MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets 30
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 30
Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer 30
Dietary restriction: could it be considered as speed bump on tumor progression road? 29
Well-being among Italian medical oncologists: An exploratory study 29
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer 28
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet 28
Multisciplinary management of patients with liver metastasis from colorectal cancer 27
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 27
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 27
What to look for in cell-free DNA from breast cancer patients 27
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 27
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression 27
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 27
Liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience 27
The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer 27
The role of microRNAs in cancer: Diagnostic and prognostic biomarkers and targets of therapies 26
Immunotherapy: Is a minor god yet in the pantheon of treatments for lung cancer? 26
New generation anaplastic lymphoma kinase inhibitors 25
Immunotherapy for recurrent ovarian cancer: A further piece of the puzzle or a striking strategy? 24
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment 24
Monoclonal antibodies and antibody fragments: State of the art and future perspectives in the treatment of non-haematological tumors 23
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 22
Petals and thorns in programmed death-ligand 1 testing: Is all non–small cell lung cancer diagnostic material suitable? 22
Totale 5.329
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.816
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.816
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202212 0 0 5 0 2 0 0 0 1 0 2 2
2022/20235 1 0 1 0 1 0 0 0 0 0 1 1
2023/2024177 0 0 0 3 1 3 1 4 22 7 11 125
2024/20251.303 40 104 41 19 212 250 21 46 101 246 107 116
2025/20263.777 180 137 239 240 435 111 259 251 435 603 460 427
2026/2027456 216 240 0 0 0 0 0 0 0 0 0 0
Totale 5.784